1. Introduction {#s0005}
===============

The gut microbiota is associated with metabolic disorders such as obesity and type 2 diabetes. Since the discovery of a link between gut microbiota and obesity in 2006 ([@bb0230], [@bb0105]), increasing evidence has been presented to suggest a causal relationship between gut microbiota and metabolic disorders ([@bb0205]).

One of the mechanisms postulated to explain this relationship is the metabolic endotoxemia hypothesis, which links gut microbes to low-grade inflammation and further to metabolic disorders ([@bb0020], [@bb0025]). In experimental animals ([@bb0195], [@bb0015]) and also in humans ([@bb0215], [@bb0100]), obesity and metabolic disorders have been associated with an impaired gut barrier, which may lead to increased translocation of endotoxins ([@bb0080], [@bb0200]), especially in connection with a Western diet ([@bb0155]). These highly inflammatory components can ultimately lead to tissue inflammation and, consequently, metabolic disorders ([@bb0020]).

Dietary recommendations have been put forward to try to prevent metabolic disorders. In the Finnish Diabetes Prevention Study, carried out in a large cohort of middle-aged participants with impaired glucose tolerance, a simple lifestyle intervention reduced the risk of diabetes by 58% compared to control ([@bb0225]). Of those subjects with excellent adherence to the intervention program, meeting four of the five intervention goals, none developed type 2 diabetes. Still, in the general population, the prevalence of metabolic disorders is rapidly increasing, and supportive prevention options---such as those targeting the gut microbiota---need to be developed to support current standards of care.

Probiotics are live micro-organisms that confer health benefits to the host ([@bb0055]), whereas prebiotics are fibers that selectively improve the growth of beneficial gut microbes ([@bb0045]). In experimental animals, we have previously shown that *Bifidobacterium animalis* ssp. *lactis* 420 (B420) prevented weight gain, improved insulin sensitivity, as well as reduced endotoxemia and tissue inflammation ([@bb0005], [@bb0200], [@bb0210], [@bb0040]). The probiotic B420 has been given to humans in earlier clinical trials, albeit at quite low doses ([@bb0085], [@bb0175], [@bb0090]), but its potential *anti*-obesity effects have remained unexplored. The prebiotic employed in the current study, Litesse® Ultra polydextrose (LU), is a randomly cross-linked polymer of glucose, which remains undigested by the host and may increase the number of *Bifidobacteria* in a colonic continuous culture system ([@bb0165]). Its administration has been reported to induce satiation ([@bb0060]) and to ameliorate the glycemic response to a glucose load ([@bb0065]), indicating potential benefits for weight maintenance and metabolic health.

To date, there is no conclusive evidence for the ability of probiotics to control body fat mass in humans. Despite a fair amount of promising clinical findings ([@bb0185], [@bb0070], [@bb0075], [@bb0140]), randomized controlled trials demonstrating beneficial probiotic effects in the primary statistical analysis of a well-powered study conducted according to Good Clinical Practice (GCP) are lacking. Only few studies on prebiotics have shown effects on weight management ([@bb0150], [@bb0110]). Furthermore, no clinical trials have explored probiotics and prebiotics alone and in combination to assess their potential synergistic benefits for metabolic health. Therefore, we conducted a double-blind, randomized, placebo-controlled, multi-center clinical trial adhering to the GCP principles to investigate the effects of a probiotic (B420) and a prebiotic (LU) on weight management and an extensive panel of mechanistic parameters, including markers of low-grade inflammation, adipose tissue metabolism, bacterial translocation and fecal short-chain fatty acids.

2. Materials and Methods {#s0010}
========================

This double-blind, randomized, parallel, placebo-controlled clinical trial was conducted in four clinical research centers in southern Finland: VL-Medi Oy (Helsinki), Clinical Research Services Turku (Turku), FinnMedi Oy (Tampere) and Kerava Health Care Center (Kerava). All research procedures performed in this trial were in strict accordance with a pre-defined protocol, and adhered to international GCP guidelines and the Declaration of Helsinki. The study was approved by the Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa and all participants signed informed consent prior to participation. This study is registered in [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0015} with the identifier [NCT01978691](ctgov:NCT01978691){#ir0020}.

2.1. Participants {#s0015}
-----------------

Eligible participants were 18--65 years old with a body mass index (BMI) between 28.0--34.9 and a waist to hip ratio of ≥ 0.88 for males and ≥ 0.83 for females.

Exclusion criteria were, briefly: diagnosed type 1 or type 2 diabetes or cardiovascular disease, or use of related medication; use of laxatives, fiber supplements or probiotics in the previous 6 weeks; inflammatory disorders and use of immunomodulatory drugs; history of bariatric surgery; use of *anti*-obesity drugs in the previous 3 months; recent (last 2 months) or on-going antibiotic use; excessive use of vitamin D supplementation; active or recent (last 3 months) participation in a weight loss program or weight change of 3 kg during the past 3 months; pregnant or planning pregnancy within 6 months or breastfeeding women; drug or alcohol abuse; and other reasons identified by the Investigator.

2.2. Intervention, Compliance and Stability {#s0020}
-------------------------------------------

All study products were obtained from DuPont Nutrition and Health (Madison, WI, USA) in sachets. The study arms were: 1) Placebo, microcrystalline cellulose 12 g/day; 2) B420, 10^10^ CFU/day in 12 g of microcrystalline cellulose (B420); 3) LU, 12 g/day; and 4) B420, 10^10^ CFU/day in 12 g of LU (LU + B420). Microcrystalline cellulose was chosen as placebo because it contains virtually no energy and is less fermented by gut microbes than alternative dietary fibers. Participants were provided with commercially available fruit smoothie products and instructed to mix the contents of one sachet into a 250 ml bottle of smoothie (130 kcal) each day while otherwise maintaining their regular diet. The smoothies were provided to the subjects to mask subtle differences in the study products and to standardize the matrix in which the products were consumed.

Following separate visits for screening and baseline assessments, participants used the study product for six months, during which they came for clinic visits at 2 months, 4 months and 6 months, with in-between telephone contacts to track compliance and potential adverse events. After completing the intervention, participants came for one more follow-up clinic visit one month after the end of the dietary intervention (month 7).

Compliance was monitored with three different methods: 1) Participants were asked to report product intake on a specific check-list, 2) Participants were asked to return all used and unused sachets to the site to count the number of opened sachets per the number of treatment days, and 3) Fecal samples were analyzed for the presence of B420 with qPCR from all participant who returned a fecal sample at the six-month visit. Details of the qPCR detection procedures are reported in the Supplemental Materials and Methods. In the Intention-to-Treat (ITT) population, the average calculated compliance (method 2) was 86% across groups, while in the B420 and LU + B420 groups the bacterial strain was detected in the feces of 82% of participants. The primers used for qPCR were also able to detect certain other *Bifidobacterium animalis* ssp. *lactis* strains such as HN019, Bl-04 and Bi-07, but not Bb12. Four participants (8%) in the Placebo group and seven (15%) in the LU group tested positive in the qPCR assay (Table S1).

Product stability was monitored throughout the study. The minimum target activity for B420 was planned at 1 × 10^10^ CFU/day. The dose of B420 at the time of packaging was 1.4 × 10^10^ CFU/day in the B420 group and 1.3 × 10^10^ CFU/day in the LU + B420 group to account for loss of stability during the study. Sachets returned from the study participants were re-tested for probiotic cell count at the end of the study with the following results: B420 1.1 × 10^10^ CFU/day, and LU + B420 1.1 × 10^10^ CFU/day, demonstrating excellent stability of the study probiotic. There were no contaminations in the Placebo and LU products.

2.3. Body Composition-Related Outcomes {#s0025}
--------------------------------------

The pre-defined primary outcome of the present study was the relative change in body fat mass from baseline to end-of-treatment (6 months). Body fat mass was measured with a dual-energy X-ray absorptiometry (DEXA) scan at qualified private medical centers. In addition, body fat mass and lean body mass were recorded as total and from individual regions of the body (android, gynoid, trunk, legs, arms). Other obesity-related outcomes included body weight and waist and hip circumference, which were measured with calibrated weighing scales and tape measures, respectively.

2.4. Clinical Laboratory Outcomes {#s0030}
---------------------------------

At the clinic visits (baseline, 2 months, 4 months, 6 months and follow-up), blood was drawn in the morning from fasting participants and sent from all sites to a certified central laboratory (United Medix Laboratories, Finland) for analysis of serum high-sensitivity C-reactive protein (hsCRP), serum glucose, serum insulin, blood glycosylated hemoglobin (HbA1c), serum lipids (total cholesterol, LDL, HDL and triglycerides) and serum cortisol. The homeostatic model assessment of insulin resistance (HOMA-IR) was calculated from fasting glucose and insulin levels (\[glucose in mmol/l\] \* \[insulin in mU/l\] / 22.5). Serum liver markers (ASAT, ALAT, gamma-glutamyltransferase) were also analyzed at the central laboratory to monitor product safety.

2.5. Exploratory Laboratory Outcomes {#s0035}
------------------------------------

The following blood biomarkers were analyzed with ELISA: interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), interleukin-1beta (IL-1β), plasminogen activator inhibitor 1 (PAI-1), vascular cell adhesion protein 1 (VCAM-1), intracellular adhesion molecule 1 (ICAM-1), *E*-selectin, sCD14, leptin, monocyte chemoattractant protein 1 (MCP-1), adiponectin, zonulin, angiopoietin-like protein 4 (angptl4), oxidized LDL cholesterol (oxLDL) and ApoB-48. The employed assay kits and their performance characteristics (coefficients of variation) are detailed in Supplementary Materials and Methods.

For lipopolysaccharide (LPS) analyses, serum samples were diluted 1:100, heat-treated for 45 min at 60 °C, and assayed in triplicate using the Limulus Amebocyte Lysate (LAL) kinetic chromogenic method (Charles River). The quantitation limit was 48 EU/l.

2.6. Analysis of Acidic Fermentation Products in Fecal Samples {#s0040}
--------------------------------------------------------------

Fecal short-chain fatty acids (SCFA) were analyzed with gas chromatography, as detailed in the Supplemental Materials and Methods.

2.7. Food Intake and Exercise Measurements {#s0045}
------------------------------------------

Food intake was measured with a 5-day food diary at baseline, 2 months and 6 months (end of intervention) as detailed in the Supplemental Materials and Methods.

Habitual exercise was captured with a simple three-point questionnaire and calculated into metabolic equivalents (MET h/day), as previously described ([@bb0095]).

2.8. Adverse Events {#s0050}
-------------------

Investigators asked study participants about adverse events at every study visit. All possible adverse events were recorded and coded according to MedDRA. The adverse events were classified by the Investigator according to severity (mild, moderate, severe) and possible relationship to treatment (unrelated, unlikely, possible, probable, not assessable).

2.9. Sample Size Determination {#s0055}
------------------------------

A one-way analysis of covariance (ANCOVA) was used to analyze the primary outcome, with baseline body fat mass as covariate. The mean relative change from baseline to 6 months in body fat mass was assumed to be 1% in the active treatment groups compared to the placebo group, and the common standard deviation was expected to be 2%. With these assumptions, 43 participants per group (172 in total) was calculated to give above 80% power to reject a null hypothesis of no difference between the active treatments compared to placebo with a one-way ANOVA, using a 5% level of significance. The power for the ANCOVA model was expected to be similar or slightly higher than for an ANOVA model. In order to compensate for an expected drop-out rate of approximately 23.5%, a total of 225 participants were randomized into the study.

2.10. Randomization and Blinding {#s0060}
--------------------------------

The randomization scheme (1:1:1:1 allocation) was generated using a computerized procedure into blocks of four randomization codes each. Boxes of investigational product were labeled with the corresponding randomization code and study centers were advised to always use the smallest available randomization code and corresponding study product. The randomization code was generated by the contract research organization Smerud Medical Research Finland Ab Oy (Kirkkonummi, Finland). The participants, the site personnel, the study monitor, the statistician and sponsor\'s representatives were all blinded to the randomization until the end of the intervention phase, when all data for primary and secondary outcomes, adverse events and compliance had been collected and validated. The study populations were defined prior to breaking the treatment code. Exploratory outcomes were assayed in a blinded fashion, but were not included in the blind data review process.

2.11. Statistical Methods {#s0065}
-------------------------

The primary and pre-determined statistical analysis was an ANCOVA to compare changes from baseline to end-of-intervention. Baseline values were used as covariates when they were significant in the model. For the ITT population, the last observation was carried forward for missing observations. All group-wise comparisons were performed using Dunnett\'s adjustment for multiple testing. A factorial analysis (two-way ANCOVA) was conducted post-hoc after unblinding, because of the lower number of participants in the B420 group compared to the other groups. There was no apparent reason for the higher number of exclusions in the B420 group, since the reasons for exclusion were similar across all groups.

Data for LPS, hsCRP and IL-6 were considered non-normally distributed. Data for hsCRP and IL-6 were analyzed with ANCOVA and Dunnett\'s adjustment after log-transformation. Data for LPS were analyzed with the Kruskal-Wallis test, with Dwass, Steel, Critchlow-Fligner analysis of between-group comparisons. Correlations between changes from baseline to end-of-study for the different markers were calculated with Spearman correlation.

All data were analyzed with SAS version 9.3 using a significance level of 0.05.

3. Results {#s0070}
==========

3.1. Recruitment and Participant Flow {#s0075}
-------------------------------------

All 225 participants were randomized at four centers in southern Finland between December 2013 and October 2014, and the last participant completed the last follow-up visit in May 2015. Study participants were randomized to four groups for a six-month intervention and a one-month follow-up period: 1) Placebo, 12 g/day of microcrystalline cellulose; 2) LU, 12 g/day; 3) B420, 10^10^ Colony Forming Units (CFU) /day in 12 g microcrystalline cellulose; 4) LU + B420, 10^10^ CFU/day of B420 in 12 g/day LU.

The study populations and reasons for exclusions are shown in [Fig. 1](#f0005){ref-type="fig"}. Of the 225 randomized participants, the Investigator excluded one person from the study due to very high cholesterol levels, before the participant had taken any study product. Therefore, the total population analyzed for adverse events included 224 participants. The ITT population contained all 209 participants who were analyzed for any variable after the baseline visit, whereas the Per Protocol (PP) population included, as defined in the protocol, all 134 participants who completed the study without major protocol violations and who had at least more than one study visit completed. A Blind Data Review process prior to unblinding the study detailed the major protocol violations as follows: 1) \< 80% of study product compliance or \> 7 consecutive days of non-compliance; 2) Baseline or 6-month visit not completed; 3) Participant randomized against inclusion and exclusion criteria (e.g. use of high-dose vitamin D supplements); and 4) Use of systemic antibiotics during the intervention period. In addition, three participants were excluded from the PP population for body composition measurements for not completing the measurement within ten days after discontinuing treatment. None of the participants were reallocated to another group for analysis.

The demographics of the ITT and PP populations are shown in [Table 1](#t0005){ref-type="table"} and were similar among the different treatment groups. Statistical conclusions for the ITT and PP populations differed greatly, and therefore drop-outs and protocol violations---which are common especially in long intervention studies such as this---were considered to have a significant impact on the outcomes. Consequently, the present report is mainly focused on the protocol-compliant PP population. Main outcomes for the ITT population can be found in Table S2.

3.2. Adverse Events and Safety Parameters {#s0080}
-----------------------------------------

All symptoms occurring during the study were documented and rated for severity and potential relationship with the study products. There were no major differences in the distribution of adverse events across groups. Over the course of 7 months, 199 of 224 study participants reported at least one adverse event, out of which 133 were potentially product-related. Adverse events are summarized in Table S3. Gastrointestinal symptoms were generally mild, and the median duration of the cases of diarrhea and loose stools was three days. There were no changes in measured safety parameters: blood pressure, heart rate and liver enzymes (Table S3).

3.3. B420 with or without LU Controls Body and Trunk Fat Mass, and Show Synergistic Effects on Lean Body Mass {#s0085}
-------------------------------------------------------------------------------------------------------------

The primary outcome of this study was the relative change in body fat mass from baseline to the end of the intervention period (6 months). Body composition was measured with DEXA every two months during the intervention and at the follow-up after one month. In the ITT population, there were no statistically significant differences between the active treatment groups and Placebo in the changes in total body fat mass ([Fig. 2](#f0010){ref-type="fig"}A). In the PP population, however, the LU + B420 group showed a significant reduction in the change in total body fat mass compared to Placebo ([Fig. 2](#f0010){ref-type="fig"}B), resulting in an average difference of 1.4 kg in total body fat between the groups. The effect seemed to persist throughout the one-month wash-out period ([Fig. 2](#f0010){ref-type="fig"}C). The difference in body fat mass was most noticeable in the trunk area and demonstrated a similar, although non-significant pattern in the abdominal (i.e. android) area ([Fig. 2](#f0010){ref-type="fig"}D--E). In other regions of the body LU + B420 had no effect. LU and B420 (alone) were not statistically different from Placebo in any of the above mentioned variables. For absolute values in all measured areas of the body in the PP population, please refer to Table S4. Changes in total body fat mass per the following subgroups are shown in Fig. S1: men vs. women, low vs. high baseline fat intake, and those in the ITT population who used systemic antimicrobials during the study. Markers of glucose metabolism are presented in Table S5, and cardiovascular biomarkers in Table S6.

Because of the lower number of observations in the B420 group (*n* = 24) compared to the other groups (*n* = 35--37), we decided to conduct a post-hoc factorial analysis to evaluate the independent effects of B420 and LU in the PP population. In the PP population, there were significant differences between the B420 and Placebo groups in their changes in total body fat mass (*P* = 0.002), trunk fat mass (*P* = 0.0002) and android fat mass (*P* = 0.004), indicating that the probiotic itself could be effective for controlling fat mass, especially in the abdominal region. LU had no independent effects on these parameters.

In addition, the results for lean body mass suggested synergy between the two investigational products, LU and B420. Although neither of the products alone had an effect on lean body mass, their combination significantly increased lean body mass compared to Placebo ([Fig. 2](#f0010){ref-type="fig"}F), and the difference developed as a gradual increase from baseline, although there were no changes in the physical exercise habits in any of the groups (Fig. S2).

3.4. B420 With or Without LU Reduces Waist Circumference Compared to Placebo {#s0090}
----------------------------------------------------------------------------

The differences in body fat mass outcomes were not completely reflected in body weight ([Fig. 2](#f0010){ref-type="fig"}G). In fact, only the B420 group showed any trend towards a reduction in body weight (*P* = 0.15) in the PP population, whereas in the LU + B420 group, the reduction in body fat mass was counterbalanced with an increase in lean body mass. In the factorial analysis, there was a significant effect for B420 (*P* = 0.03), but no effect for LU (*P* = 0.80) compared to placebo in the PP population. The LU + B420 group also showed a 2.7% (2.6 cm) reduction in waist circumference (*P* = 0.047) ([Fig. 2](#f0010){ref-type="fig"}H) and a trend (*P* = 0.079) towards a 1.3% (1.4 cm) smaller hip circumference compared to Placebo ([Fig. 2](#f0010){ref-type="fig"}I). According to the factorial analysis, there was a significant 2.4% difference in the change in waist circumference between B420 and Placebo (− 2.4 cm compared to Placebo) (*P* = 0.004).

3.5. Six-Month Supplementation with B420 and LU + B420 Reduces Energy Intake Compared to Placebo {#s0095}
------------------------------------------------------------------------------------------------

We measured dietary intake with 5-day food diaries at baseline and at 2 and 6 months after study start. There were no differences between the groups in baseline dietary intake (Table S7). B420 and LU + B420 reduced energy intake by approximately 300 kcal/day and 210 kcal/day compared to Placebo ([Table 2](#t0010){ref-type="table"}). This was associated with a reduced intake of dietary fat and fiber in the B420 group, but without differences in the relative proportion of fat in the diet.

B420 also increased plasma cortisol concentrations (Fig. S3), which has been suggested to increase energy expenditure and fat oxidation ([@bb0010]) and to suppress inflammation. Increased plasma cortisol may also be related to an adverse stress response ([@bb0245]), however, there was only one psychiatric-related adverse event in the B420 group: a mild worsening of depression, which also occurred in one participant in the Placebo group. The investigator evaluated both cases as unrelated to the study product.

3.6. Changes in Fat Mass Correlate with Circulating Zonulin and hsCRP {#s0100}
---------------------------------------------------------------------

Levels of circulating zonulin, a potential marker of intestinal permeability ([@bb0035], [@bb0130]), seemed to remain consistently lower throughout the study in the B420 and LU + B420 groups compared to Placebo and LU ([Fig. 3](#f0015){ref-type="fig"}A), which was reflected as a trend towards a difference between B420 and Placebo in the factorial analysis (*P* = 0.063) ([Table 3](#t0015){ref-type="table"}). Changes in zonulin were also statistically significantly correlated with changes in trunk fat mass (*r* = 0.349, *P* \< 0.0001) ([Fig. 3](#f0015){ref-type="fig"}B), indicating a potential mechanistic link between the two. This correlation was only evident in the LU + B420 group.

Changes in hsCRP were somewhat similar to the changes in zonulin ([Fig. 3](#f0015){ref-type="fig"}C). Although there were no differences between groups in the primary analysis, a factorial analysis showed a tendency towards a reduction in hsCRP in B420 vs. Placebo (*P* = 0.073) ([Table 3](#t0015){ref-type="table"}). Changes in hsCRP were also significantly correlated with changes in trunk fat mass (*r* = 0.217, *P* = 0.012) ([Fig. 3](#f0015){ref-type="fig"}D), but again only in the LU + B420 group. Changes in hsCRP were also significantly correlated with changes in zonulin (Spearman correlation *r* = 0.199, *P* = 0.021).

LU + B420 appeared to increase LPS level in plasma compared to Placebo (Kruskal-Wallis *P* = 0.009), although the changes were small and LPS level remained below or close to the detection limit in most participants. There was no effect on soluble cluster of differentiation 14 (sCD14), a co-receptor of LPS ([Table 3](#t0015){ref-type="table"}), underlining the lack of inflammatory response to the slightly increased LPS levels. There were also no differences in IL-6 levels ([Table 3](#t0015){ref-type="table"}). Concentrations of TNF-α and IL-1β were below the lower limit of quantitation in 95 and 97% of the samples, respectively.

The corresponding outcomes for the ITT population are shown in Table S8. Adipose tissue-related biomarkers are shown in Table S9.

3.7. Increased Production of Bacterial Metabolites in Feces {#s0105}
-----------------------------------------------------------

In the factorial analysis, B420 increased the concentration of fecal propionic acid, butyric acid and valeric acid (*P* \< 0.05) ([Table 4](#t0020){ref-type="table"}, data for ITT population shown in Table S10.), which indicated an increased metabolism of non-digestible polysaccharides and suggests changes in the composition of the gut microbiota. A tendency for similar changes was noted for acetic acid, although the factorial analysis was not statistically significant (*P* = 0.13). In the primary statistical analysis, only valeric acid was significantly increased by B420; there were no other statistically significant differences between the groups. Total fecal SCFA concentrations were also increased by B420 in the factorial analysis.

4. Discussion {#s0110}
=============

Over the past decade, advances in science have established a link between gut microbes and obesity, raising interest in developing probiotics and prebiotics for weight management. This study shows consistent results towards an improvement in weight management -related parameters in the probiotic and synbiotic groups, including total body fat mass, trunk fat mass, waist circumference, and energy intake in the Per Protocol population. Furthermore, our study demonstrates synergy between a probiotic and a prebiotic fiber supplement in promoting lean body mass accumulation. We also present results on biomarkers associated with gut barrier function, reduced inflammatory tone and intestinal microbiota metabolism that suggest a potential mechanism of action for B420 and LU + B420 in reducing body fat mass.

We have previously shown that B420 reduces body fat mass gain in mice that are fed a high-fat diet ([@bb0200]). In the current study, only the LU + B420 group significantly reduced total body fat mass compared to Placebo in the PP population, while there were no differences in the ITT population. A post-hoc factorial analysis showed that B420 alone had a significant effect in both the ITT and PP population. The differences between the treatment groups were consistent across several outcomes, providing further support to the previous results obtained in experimental animals.

We conducted statistical analyses on both, ITT and PP populations, with different conclusions. In the ITT populations we used for missing observations the Last Observation Carried Forward method that is a widely accepted approach, but can alter the conclusions of very long studies, which are prone to drop-outs and protocol violations. The findings of the PP population can be considered as being better representative of the effect of the investigated products, but they, in turn, are prone to bias from participant drop-outs. In this study, our PP population included 64% of the ITT population, mainly due to drop-outs, non-compliance and use of systemic antimicrobials. This weakens the statistical power in the PP population and warrants further studies to support the present findings.

In the current study, the study participants in the Placebo group gained approximately 1 kg (1.1%) of weight compared to baseline. This weight gain was not due to increased energy intake from the smoothie vehicle, as energy intake did not change in the Placebo group (− 23 kcal). On the contrary, the LU + B420 and B420 groups showed considerable reductions in their energy intake (− 230 and − 320 kcal/day, respectively), while body weight and body fat mass did not differ from baseline, suggesting that B420 and LU + B420 normalized energy balance by reducing energy intake to a level that maintains, rather than increases, body fat mass.

According to the Helsinki Health Study, steady weight gain over time is rather common among an average Finnish middle-aged population ([@bb0120]), as approximately 30% gained at least 5 kg weight during a 5--7-year follow-up period. Our overweight and obese study population (BMI 28--34.5) may have been more prone to weight gain than the average population in the Helsinki Health Study.

Four clinical studies involving healthy, overweight and/or obese participants have investigated the effects of micro-organisms on weight management or body fat mass ([@bb0070], [@bb0075], [@bb0125], [@bb0185]). The effect size seen in the current study (6.7% difference in trunk fat between LU + B420 and Placebo) is quite comparable to that seen in 12-week interventions with *Lactobacillus gasseri* SBT2055 where abdominal fat was reduced by approximately 4.5% compared to placebo ([@bb0070], [@bb0075]). It is difficult to compare the employed statistical methodology, however, because it remains unclear which participants were included in the analyses. In comparison, intake of *Bifidobacterium breve* B-3 reduced body fat mass by 0.6 kg compared to placebo within 12 weeks ([@bb0125]). It should also be noted that the study participants in these three studies were Japanese whereas the present study was conducted on a Western population.

In a Canadian study population, a combination of *Lactobacillus rhamnosus* CGMCC1.3724 (LPR), inulin and oligofructose helped to further reduce weight (2.7 kg) and total body fat mass (1.8%) during a weight-loss and weight maintenance period, but only in women ([@bb0185]). In the present study, we did not find marked differences between the observed effects in men and women.

In terms of effect size, it is difficult to compare probiotics to pharmaceuticals, because the latter have been tested for weight loss instead of fat mass loss, and they are accompanied by a weight-loss program. However, the reported changes in body weight at six months compared to placebo have been: − 3.5 kg for orlistat ([@bb0220]), − 5.5% for liraglutide ([@bb0160]), and − 3.2% for locaserin ([@bb0135]), compared to − 1.4 kg (− 4.5%) with LU + B420 and − 1.0 kg (− 3.0%) with B420 in fat mass in the present study. It should be noted that probiotics are taken orally once per day, while orlistat is taken multiple times per day and liraglutide requires a daily subcutaneous injection. Therefore, probiotics and synbiotics could be a safe and convenient, non-pharmaceutical support for controlling body fat mass, especially prophylactically.

The results of this study showed that changes in circulating zonulin levels correlated with changes in trunk fat mass, but only in the LU + B420 group, indicating a potential mechanistic relationship between zonulin and trunk fat mass. Also, B420 tended to reduce levels of circulating zonulin. Zonulin is the human analogue of the zonula occludens toxin produced by *Vibrio cholera* ([@bb0235], [@bb0035]). It selectively increases intestinal permeability in jejunum and ileum ([@bb0235]), and its release is induced by certain gut microbes, especially pathogens ([@bb0030]), indicating that zonulin could act as a mechanistic link between changes in the gut microbiota and gut barrier function.

When measured from circulation, zonulin has been linked with insulin resistance ([@bb0130]), type 2 diabetes ([@bb0240]), higher BMI ([@bb0130]) and non-alcoholic fatty liver disease ([@bb0145]). The link between circulating zonulin and intestinal zonulin remains somewhat elusive, since circulating zonulin might not originate only from the gut ([@bb0235]). Nevertheless, decreased circulating zonulin is associated with a decreased lactulose/mannitol ratio, an indicator of intestinal permeability ([@bb0180], [@bb0115]), as well as fewer postoperative infection complications ([@bb0115]). Furthermore, type 1 diabetic patients and their relatives were found to have increased circulating zonulin levels that correlated with intestinal permeability ([@bb0190]). According to these findings, it is plausible that the changes in circulating zonulin, as seen in the present study, are related to an improvement in gut barrier function.

Improved gut barrier function is hypothesized to reduce metabolic endotoxemia, especially the concentration of highly inflammatory LPS, and reduce low-grade inflammation ([@bb0020]). Our earlier studies have shown that B420 improves epithelial barrier function in cell culture ([@bb0170]) and reduces epithelial translocation of *E. coli* as well as circulating LPS levels in mice ([@bb0005], [@bb0200]). We have also recently shown that LU + B420 modulates the intestinal immune system in mice and changes the microbial DNA signature in adipose tissue, which were associated with improvements in glucose metabolism ([@bb0040]).

In this present study we saw a subtle increase in plasma LPS levels without activation of inflammatory responses. LPS levels were below or close to the detection limit both at baseline and at the end of intervention, questioning the clinical relevance of this LPS increase. However, this finding could point to a different manifestation of metabolic endotoxemia between mice and humans. The LAL methodology detects total LPS level in a sample and does not specify which bacterial species the LPS molecules originate from. It has been reported that the LPS levels detected with the LAL method may considerably differ from their cytokine-producing potency ([@bb0050]). Thus, although the level of total LPS was increased with LU + B420 treatment, its quality and inflammatory potency may have also been changed by the treatment. This hypothesis was supported by the tendency towards reduced hsCRP levels.

We did not see treatment-associated reductions in blood glucose, HbA1c, insulin or HOMA-IR in the present study. Although we recruited overweight and obese participants, baseline laboratory values indicated that the participants had normal fasting glucose (average 5.18--5.24 mmol/l) and insulin (average 7.84--9.07 mU/l) levels, leaving very little room for improvement. Previously, we have shown improvement in glucose metabolism with both B420 alone ([@bb0200], [@bb0210]) and in combination with LU ([@bb0040]). The treatments should be tested in populations with impaired glucose metabolism or in patients with type 2 diabetes.

This randomized, double-blind, placebo-controlled clinical intervention trial in overweight and obese adults presents preliminary clinical evidence that the probiotic B420 with or without Litesse Ultra polydextrose can reduce body fat mass, waist circumference, energy intake and body weight compared to placebo. Our findings are of special interest to populations who struggle to control their weight in a Western cultural environment. Additionally, B420 and LU seem to have synergistic effects in increasing lean body mass. LU alone had no effect on the parameters tested. Mechanistically, the reduction of body fat mass might be related to circulating zonulin, a potential marker of gut barrier function, and attenuated low-grade inflammation, which both support previous findings from experimental animals. Further clinical trials are warranted to confirm these effects in larger participant populations and to further elucidate the underlying mechanisms.

Funding Sources {#s0115}
===============

This study was fully funded by DuPont Nutrition & Health. DuPont, Smerud and the Principal Investigator were jointly responsible for drafting the study protocol and reports as well as interpretation of the data. The lead author of this manuscript was employed at DuPont.

Conflicts of Interest {#s0120}
=====================

This study was fully funded by DuPont Nutrition & Health. Each of the authors or their respective organizations were financially compensated by DuPont for their contribution in the study. In addition, M.S. is a shareholder of Clinical Research Services Turku, and M.C. and R.B. are founders and shareholders of Vaiomer.

Author Contributions {#s0125}
====================

Conceptualization, R.B., S.L.; Methodology, L.K.S., M.J.L., N.M., H.K.S., A.R., and S.L.; Formal Analysis, N.M.; Investigation, L.K.S., M.J.L., N.M., J.E.C., N.Y., M.T.S., M-L.L., J.L., D.A., and M.S.; Resources, M.C., M-L.L., J.L., D.A., M.S., and S.L.; Writing---Original Draft, L.K.S.; Writing---Review & Editing, M.J.L., N.M., N.Y., M.T.S., R.B., H.K.S., M.S. and S.L.; Visualization, L.K.S. and N.M; Supervision, R.B., H.K.S, A.R., and S.L.; Project Administration, L.K.S.

Appendix A. Supplementary data {#s0130}
==============================

Supplementary materialImage 1

We wish to extend our gratitude to the study participants, investigators, monitors and study nurses who enabled this study. We are especially thankful to Yvonne Peltonen for her firm study management. Also, we are thankful to Angela Paulsen and Tad Stewart from DuPont Nutrition & Health for the production and quality control of the study products, as well as to all who participated in sample analyses: Jaana Larsson-Leskelä, Henri Ahokoski, Kirsi Stenström and Sari Pohjola. We are also very grateful to Tiina Roine and Auli Väänänen for food diary data extraction.

Conflict of interest statement: LKS, MJL, NY, MTS and SL are employees of DuPont Nutrition & Health.

The research was funded by DuPont Nutrition & Health.

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.ebiom.2016.10.036>.

![Participant flow. Before unblinding the study, participants were divided into an Intention-to-Treat (ITT) population and a Per Protocol (PP) population according to adherence to the study protocol.](gr1){#f0005}

![Weight management outcomes. Change in total body fat mass from baseline to end of study (6 months of intervention) in the Intention-to-Treat (a) and Per Protocol (PP) (b) populations. Evolution of body fat mass in the PP population during intervention and at follow-up (c). Changes in trunk fat mass (d), android fat mass (e), lean body mass (f), body weight (g), waist circumference (h) and hip circumference (i) from baseline to end of study in the PP population. Body composition in panels a-f was measured with dual-energy X-ray absorptiometry. Results are expressed as mean ± 95% CI. Results were analyzed with ANCOVA and Dunnett\'s pairwise comparisons corrected for multiple testing. In the ITT population, the last observation was carried forward for the statistical analysis of participants who withdrew from the study. Solid line shows baseline; dotted line shows the level of the Placebo group. N of participants included in the statistical analysis in the Intention-to-Treat population: Placebo *n* = 53, LU *n* = 51, B420 *n* = 47, LU + B420 *n* = 48. N for the PP population: Placebo *n* = 35--36, LU *n* = 35--36, B420 *n* = 24--25, LU + B420 *n* = 37. Overall ANCOVA as follows: a) *P* = 0.46, b) *P* = 0.095, d) *P* = 0.036, e) *P* = 0.23, f) *P* = 0.30, g) *P* = 0.13, h) *P* = 0.10, i) *P* = 0.31.](gr2){#f0010}

![Correlation between serum zonulin, serum hsCRP and trunk fat mass. Evolution of zonulin (a) and hsCRP (c), and correlations between zonulin (b) and hsCRP (d) with trunk fat mass as changes from baseline to end-of-intervention (6 months) in the Per Protocol population. Panels a) and c) display changes from baseline as mean ± 95% confidence intervals at each time point. Placebo *n* = 35--36, LU *n* = 35--36, B420 *n* = 24--25, LU + B420 *n* = 36--37.](gr3){#f0015}

###### 

Baseline demographics of the Intention-to-Treat and Per Protocol populations.

Table 1

                                                   Placebo       LU            B420          LU + B420     Total
  --------------------------- -------------------- ------------- ------------- ------------- ------------- -------------
  Intention-to-Treat          *n*                  56            53            48            52            209
  Gender                      n, Male/Female       12/44         12/41         9/39          9/43          42/167
  Ethnicity                   n, Caucasian/Other   55/1          52/1          48/0          51/1          206/3
  Age, years                  mean ± SD            49.9 ± 8.5    48.8 ± 10.5   50.6 ± 10.6   47.0 ± 11.1   49.1 ± 10.2
  Weight, kg                  mean ± SD            88.5 ± 12.2   89.4 ± 9.1    88.7 ± 9.3    87.8 ± 11.0   88.6 ± 10.4
  BMI, kg/m^2^                mean ± SD            31.2 ± 2.2    31.2 ± 1.6    31.5 ± 2.2    31.3 ± 2.0    31.3 ± 2.0
  Waist circumference, cm     mean ± SD            103.0 ± 8.4   103.4 ± 6.1   102.6 ± 6.9   102.5 ± 6.9   102.9 ± 7.1
  Blood glucose, mmol/l       mean ± SD            5.24 ± 0.50   5.20 ± 0.62   5.18 ± 0.43   5.19 ± 0.42   5.20 ± 0.50
  Total Cholesterol, mmol/l   mean ± SD            5.23 ± 0.87   5.22 ± 1.00   5.26 ± 1.08   5.50 ± 0.96   5.30 ± 0.97
  LDL Cholesterol, mmol/l     mean ± SD            3.10 ± 0.77   3.08 ± 0.82   3.25 ± 0.91   3.38 ± 0.89   3.20 ± 0.85
  Triglycerides, mmol/l       mean ± SD            1.22 ± 0.61   1.27 ± 0.53   1.27 ± 0.56   1.29 ± 0.61   1.26 ± 0.58
  Per-Protocol                *n*                  36            36            25            37            134
  Gender                      n, Male/Female       10/26         8/28          7/18          6/31          31/103
  Ethnicity                   n, Caucasian/Other   36/0          35/1          25/0          37/0          133/1
  Age, years                  mean ± SD            48.3 ± 8.6    48.6 ± 10.9   49.1 ± 11.9   47.1 ± 10.9   48.2 ± 10.4
  Weight, kg                  mean ± SD            88.7 ± 12.5   89.7 ± 9.4    88.9 ± 10.3   87.7 ± 11.3   88.7 ± 10.9
  BMI, kg/m^2^                mean ± SD            31.0 ± 2.2    31.2 ± 1.6    30.9 ± 1.9    31.2 ± 2.0    31.1 ± 1.9
  Waist circumference, cm     mean ± SD            102.1 ± 7.5   103.3 ± 6.6   103.3 ± 7.5   102.1 ± 7.3   102.7 ± 7.2
  Blood glucose, mmol/l       mean ± SD            5.21 ± 0.54   5.18 ± 0.68   5.16 ± 0.35   5.22 ± 0.42   5.20 ± 0.52
  Total Cholesterol, mmol/l   mean ± SD            5.16 ± 0.86   5.24 ± 1.01   5.14 ± 0.86   5.58 ± 0.90   5.29 ± 0.92
  LDL Cholesterol, mmol/l     mean ± SD            3.05 ± 0.75   3.12 ± 0.73   3.12 ± 0.66   3.39 ± 0.84   3.17 ± 0.76
  Triglycerides, mmol/l       mean ± SD            1.20 ± 0.67   1.25 ± 0.54   1.33 ± 0.58   1.36 ± 0.66   1.28 ± 0.62

###### 

Changes in food intake during the study, as assessed with 5-day food diaries (Per Protocol population).

Table 2

                                                          Energy intake (kcal/day)   Fat intake (g/day)   Relative fat intake (% kcal)                   Fiber intake (g/day)                                                                                                                                                                               
  ------------------------------------------ ------------ -------------------------- -------------------- ---------------------------------------------- ---------------------- --------- --------- -------------------------------------------- ---- -------- -------- ----------- ---- ---------- ---------- -------------------------------------------- ----
  Placebo[a](#tf0010){ref-type="table-fn"}   *Baseline*   33                         2240 ± 510           0                                              --                     33        96 ± 32   0                                            --   33       38 ± 7   0           --   33         21 ± 6.6   0                                            --
  *Month 2*                                  34           2270 ± 570                 31                   57 ± 500                                       34                     90 ± 32   31        − 4.9 ± 32                                   34   35 ± 7   31       − 2.7 ± 6   34   20 ± 7.3   31         − 1.3 ± 7                                    
  *Month 6*                                  36           2180 ± 460                 33                   − 23 ± 600                                     36                     92 ± 31   33        − 2.2 ± 43                                   36   37 ± 7   33       − 0.6 ± 8   36   20 ± 5.6   33         − 1.2 ± 6                                    
  LU                                         *Baseline*   33                         2210 ± 650           0                                              --                     33        92 ± 29   0                                            --   33       38 ± 5   0           --   33         22 ± 7.9   0                                            --
  *Month 2*                                  35           2170 ± 640                 33                   − 15 ± 430                                     35                     93 ± 31   33        2.2 ± 23                                     35   39 ± 5   33       0.9 ± 6     35   20 ± 9.2   33         − 1.5 ± 7                                    
  *Month 6*                                  34           2000 ± 520                 33                   − 200 ± 510                                    34                     80 ± 27   33        − 12 ± 24                                    34   35 ± 4   33       − 2.0 ± 6   34   21 ± 9.3   33         − 1.1 ± 6                                    
  B420                                       *Baseline*   24                         2200 ± 380           0                                              --                     24        94 ± 22   0                                            --   24       38 ± 5   0           --   24         24 ± 6.6   0                                            --
  *Month 2*                                  22           2130 ± 380                 22                   − 120 ± 250                                    22                     87 ± 26   22        − 9.7 ± 18                                   22   36 ± 7   22       − 2.4 ± 6   22   19 ± 5.7   22         − 5.6 ± 5                                    
  *Month 6*                                  22           1900 ± 370                 22                   − 320 ± 300[⁎](#tf0005){ref-type="table-fn"}   22                     74 ± 22   22        − 22 ± 19[⁎](#tf0005){ref-type="table-fn"}   22   35 ± 6   22       − 4.0 ± 6   22   19 ± 6.8   22         − 5.6 ± 6[⁎](#tf0005){ref-type="table-fn"}   
  LU + B420                                  *Baseline*   35                         2090 ± 640           0                                              --                     35        87 ± 32   0                                            --   35       37 ± 6   0           --   35         20 ± 6.2   0                                            --
  *Month 2*                                  34           1990 ± 440                 33                   − 110 ± 530                                    34                     79 ± 26   33        − 8.6 ± 29                                   34   35 ± 7   33       − 1.7 ± 7   34   16 ± 4.0   33         − 4.2 ± 6                                    
  *Month 6*                                  31           1870 ± 440                 29                   − 230 ± 640[⁎](#tf0005){ref-type="table-fn"}   31                     74 ± 31   29        − 10 ± 29                                    31   35 ± 6   29       − 1.2 ± 5   31   16 ± 5.1   29         − 3.9 ± 5                                    

= Significant difference from Placebo, *P* \< 0.05 (Dunnett\'s test, corrected for multiple comparisons). Only changes from baseline to month 6 were statistically compared between groups.

Women with energy intake \< 80% and men with energy intake \< 85% of basal metabolic rate excluded from dietary intake analyses. The energy content of the smoothie vehicle is included in the results.

###### 

Changes in markers of endotoxemia and low-grade inflammation (Per Protocol population).

Table 3

                                   Placebo        LU             B420                                          LU + B420                                *Overall P*                              *Factorial P B420*                       *Factorial P LU*
  ----------------- -------------- -------------- -------------- --------------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ------------------
  Zonulin (ng/ml)   *Baseline*     56.5 ± 12.6    55.5 ± 9.1     58.4 ± 11.4                                   64.6 ± 14.2                                                                                                                
  *Month 6*         59.7 ± 10.9    58.4 ± 12.0    57.1 ± 8.3     63.4 ± 13.0                                                                                                                                                              
  *Δ (ng/ml)*       + 3.5 ± 10.0   + 2.8 ± 8.6    − 1.2 ± 9.1    − 1.2 ± 7.0                                   0.10                                     0.063                                    0.84                                     
  ApoB-48 (μg/ml)   *Baseline*     11.0 ± 7.2     9.5 ± 6.9      11.1 ± 5.5                                    9.8 ± 4.9                                                                                                                  
  *Month 6*         11.0 ± 6.1     9.1 ± 5.4      12.6 ± 7.5     10.4 ± 5.7                                                                                                                                                               
  *Δ (*μg*/ml)*     + 0.07 ± 5.7   − 0.44 ± 5.3   + 1.53 ± 6.5   + 0.56 ± 4.0                                  0.74[a](#tf9010){ref-type="table-fn"}    0.26[a](#tf9010){ref-type="table-fn"}    0.092[a](#tf9010){ref-type="table-fn"}   
  hsCRP (mg/l)      *Baseline*     1.73 ± 1.4     2.20 ± 2.3     2.78 ± 2.6                                    2.58 ± 2.6                                                                                                                 
  *Month 6*         2.08 ± 1.3     2.43 ± 2.30    2.22 ± 2.6     2.56 ± 2.6                                                                                                                                                               
  *Δ (mg/l)*        + 0.35 ± 1.7   + 0.23 ± 1.8   − 0.56 ± 2.0   − 0.02 ± 2.0                                  0.13[a](#tf9010){ref-type="table-fn"}    0.073[a](#tf9010){ref-type="table-fn"}   0.84[a](#tf9010){ref-type="table-fn"}    
  LPS (EU/l)        *Baseline*     65 ± 115       120 ± 206      43 ± 61                                       39 ± 43                                                                                                                    
  *Month 6*         39 ± 26        101 ± 365      51 ± 76        48 ± 42                                                                                                                                                                  
  *Δ (EU/l)*        − 26 ± 108     − 13 ± 341     + 7.1 ± 39     + 9.1 ± 40[⁎](#tf9005){ref-type="table-fn"}   0.007[b](#tf9015){ref-type="table-fn"}   0.094[a](#tf9010){ref-type="table-fn"}   0.22[a](#tf9010){ref-type="table-fn"}    
  sCD14 (μg/ml)     *Baseline*     1.62 ± 0.39    1.82 ± 0.43    1.80 ± 0.37                                   1.77 ± 0.49                                                                                                                
  *Month 6*         1.80 ± 0.61    1.87 ± 0.49    1.79 ± 0.54    1.75 ± 0.43                                                                                                                                                              
  *Δ (*μg*/ml)*     + 0.18 ± 0.6   + 0.06 ± 0.5   − 0.01 ± 0.5   − 0.03 ± 0.5                                  0.43                                     0.24                                     0.78                                     
  IL-6 (pg/ml)      *Baseline*     10.5 ± 19      12.8 ± 20      9.0 ± 10                                      17.5 ± 54                                                                                                                  
  *Month 6*         9.2 ± 16       12.3 ± 13      11.2 ± 13      8.0 ± 10                                                                                                                                                                 
  *Δ (pg/ml)*       − 1.2 ± 10     − 0.54 ± 15    + 2.2 ± 13     − 9.5 ± 47                                    0.72[a](#tf9010){ref-type="table-fn"}    0.42[a](#tf9010){ref-type="table-fn"}    0.64[a](#tf9010){ref-type="table-fn"}    

Significant difference from Placebo, *P* \< 0.05 (Dunnett\'s test, corrected for multiple comparisons). Only relative changes from baseline to month 6 were statistically compared between groups.

Analyses on log-transformed data.

Non-parametric analyses.

###### 

Changes in bacterial metabolites in feces in the Per Protocol population.

Table 4

                                                                               Placebo        LU                                              B420           LU + B420                               *Overall P*                             *Factorial P B420*                      *Factorial P LU*
  ------------------------------------------------------------- -------------- -------------- ----------------------------------------------- -------------- --------------------------------------- --------------------------------------- --------------------------------------- ------------------
  Acetic acid                                                   *Baseline*     42.3 ± 16      43.0 ± 18                                       38.5 ± 21      43.7 ± 18                                                                                                               
  *Month 6*                                                     37.1 ± 14      37.6 ± 14      39.8 ± 14                                       41.3 ± 17                                                                                                                              
  *Δ*                                                           − 5.20 ± 14    − 5.76 ± 18    + 1.34 ± 24                                     − 2.60 ± 18    0.34                                    0.13                                    0.99                                    
  Propionic acid                                                *Baseline*     11.8 ± 5.1     12.6 ± 5.7                                      10.7 ± 5.2     12.6 ± 5.9                                                                                                              
  *Month 6*                                                     9.9 ± 4.0      10.6 ± 5.6     11.6 ± 4.6                                      12.3 ± 5.9                                                                                                                             
  *Δ*                                                           − 1.91 ± 4.1   − 2.00 ± 6.0   + 0.92 ± 5.8                                    − 0.31 ± 7.0   0.095                                   0.025                                   0.79                                    
  Butyric acid                                                  *Baseline*     11.5 ± 6.5     10.8 ± 6.2                                      11.7 ± 8.6     11.7 ± 6.3                                                                                                              
  *Month 6*                                                     10.2 ± 6.0     9.2 ± 4.8      13.1 ± 9.4                                      10.3 ± 5.4                                                                                                                             
  *Δ*                                                           − 1.33 ± 6.2   − 1.58 ± 5.9   + 1.35 ± 13                                     − 1.21 ± 7.2   0.45                                    0.0497                                  0.095                                   
  Valeric acid                                                  *Baseline*     1.6 ± 0.95     1.5 ± 1.1                                       1.6 ± 1.1      1.9 ± 0.9                                                                                                               
  *Month 6*                                                     1.3 ± 0.81     1.4 ± 1.0      1.8 ± 1.3                                       1.5 ± 0.9                                                                                                                              
  *Δ*                                                           − 0.31 ± 0.9   − 0.08 ± 1.4   + 0.26 ± 1.4[⁎](#tf0015){ref-type="table-fn"}   − 0.34 ± 1.0   0.083                                   0.046                                   0.43                                    
  Lactic acid                                                   *Baseline*     0.81 ± 0.89    0.67 ± 0.45                                     0.71 ± 1.04    0.65 ± 0.82                                                                                                             
  *Month 6*                                                     0.65 ± 0.69    0.88 ± 0.86    1.40 ± 2.69                                     0.60 ± 0.62                                                                                                                            
  *Δ*                                                           − 0.16 ± 0.8   + 0.22 ± 0.8   + 0.68 ± 2.2                                    + 0.02 ± 0.7   0.14[a](#tf0020){ref-type="table-fn"}   0.85[a](#tf0020){ref-type="table-fn"}   0.58[a](#tf0020){ref-type="table-fn"}   
  Branched-chain fatty acids[b](#tf0025){ref-type="table-fn"}   *Baseline*     3.86 ± 2.2     3.37 ± 2.2                                      3.70 ± 2.2     4.21 ± 2.0                                                                                                              
  *Month 6*                                                     2.77 ± 1.1     3.02 ± 1.5     3.76 ± 3.6                                      3.08 ± 1.8                                                                                                                             
  *Δ*                                                           − 1.09 ± 2.2   − 0.32 ± 2.7   + 0.06 ± 3.6                                    − 1.20 ± 1.9   0.11                                    0.13                                    0.52                                    
  Total                                                         *Baseline*     71.9 ± 25      71.9 ± 28                                       66.9 ± 33      74.7 ± 28                                                                                                               
  *Month 6*                                                     61.9 ± 22      62.7 ± 23      71.5 ± 27                                       69.1 ± 26                                                                                                                              
  *Δ*                                                           − 10.0 ± 23    − 9.5 ± 28     + 4.6 ± 41                                      − 5.6 ± 31     0.19                                    0.049                                   0.68                                    

= Significant difference from Placebo, *P* \< 0.05 (Dunnett\'s test, corrected for multiple comparisons). Only relative changes from baseline to month 6 were statistically compared between groups.

Non-parametric analyses.

Sum of isobutyric acid, isovaleric acid and 2-methyl-butyric acid.
